Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (AATD) | RxWiki

Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (AATD)

Overview[ - collapse ][ - ]

Purpose	We hypothesize that individuals with Alpha-1 Antitrypsin (AAT) deficiency have ongoing liver injury which is not detected by the usual blood tests used to look at liver function. This ongoing liver injury leads to cirrhosis in a significant number of adults with AAT deficiency.
Condition	Liver Fibrosis Alpha-1 Antitrypsin Deficiency AAT Deficiency AATD
Intervention	Device: Abdominal ultrasound Procedure: History and physical Procedure: Intravenous catheter Procedure: Blood draw Other: Liver questionnaire Procedure: Liver Biopsy Drug: Midazolam Drug: Fentanyl Drug: Lidocaine Drug: Acetaminophen Drug: Lorazepam Drug: Oxycodone/Acetaminophen Drug: Ondansetron
Phase	Phase 1
Sponsor	University of Florida
Responsible Party	University of Florida
ClinicalTrials.gov Identifier	NCT01810458
First Received	March 6, 2013
Last Updated	October 28, 2013
Last verified	October 2013

Tracking Information[ + expand ][ + ]

First Received Date	March 6, 2013
Last Updated Date	October 28, 2013
Start Date	October 2013
Estimated Primary Completion Date	April 2017
Current Primary Outcome Measures	To estimate the prevalence and histologic spectrum of liver injury in an adult with Alpha-1 Antitrypsin deficiency and a genotype of ZZ. [Time Frame: up to 30 days] [Designated as safety issue: No]An abdominal ultrasound will be done at the screening visit. A liver biopsy will be done on subjects who pass the screening process. The biopsy will be done within 30 days of the screening visit.
Current Secondary Outcome Measures	To identify environmental and host risk factors for clinically significant liver fibrosis. [Time Frame: At each study visit including screening, first liver biopsy, year 1, year 2, and year 3 visits.] [Designated as safety issue: No]A liver disease questionnaire will be done at the time of the first liver biopsy and at the year 3 study visit. A history and physical will also be completed at the screening visit, year 1 visit, year 2 visit, and year 3 visit. To define the diagnostic accuracy of non-invasive markers of fibrosis in AAT liver disease. [Time Frame: At the screening and year 3 visits.] [Designated as safety issue: No]An abdominal ultrasound will be completed at the screening visit and the year 3 visit. To explore epigenetic markers for the development of liver fibrosis. [Time Frame: Starting with the first liver biopsy and ending with the second liver biopsy done at year 3.] [Designated as safety issue: No]Liver tissue collected at the time of the first biopsy will be sent for testing which will evaluate for epigenetic markers of liver fibrosis. For subjects whose initial liver biopsy reveals liver fibrosis between stages 2 - 4, additional liver tissue will be collected at the time of the repeat biopsy done at the year 3 study visit. To quantify liver fibrosis progression. [Time Frame: At each study visit including screening, first liver biopsy, year 1, year 2, and year 3 visits.] [Designated as safety issue: No]The presence and progression of liver fibrosis will be evaluated by an abdominal ultrasound done at the screening visit, year 1 visit, year 2 visit, and year 3 visit. A liver biopsy will be done if a subject passes the screening visit and will be repeated at the year 3 study visit if the initial liver biopsy reveals liver fibrosis between stages 2 - 4.

Descriptive Information[ + expand ][ + ]

Brief Title	Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (AATD)
Official Title	Clinical Predictors and Epigenetic Markers for Liver Fibrosis in Alpha-1 Antitrypsin Deficiency
Brief Summary	We hypothesize that individuals with Alpha-1 Antitrypsin (AAT) deficiency have ongoing liver injury which is not detected by the usual blood tests used to look at liver function. This ongoing liver injury leads to cirrhosis in a significant number of adults with AAT deficiency.
Detailed Description	Our overarching hypothesis is that liver disease in adults with AAT deficiency is the result of the accumulation of the abnormally folded protein within the endoplasmic reticulum of the hepatocyte. In some individuals, the intrinsic cellular mechanisms of the hepatocyte are sufficient to clear adequate amounts of the abnormally folded protein such that liver disease does not occur. In AAT deficient individuals who develop liver disease, environmental and other genetic factors stress the hepatocyte, and the normal cellular mechanisms that maintain homeostasis are disrupted, leading to liver disease. For this proposal, our hypothesis is that the prevalence of liver disease in adults with AAT is higher than previously reported because liver injury and fibrosis is not accurately detected by available routine liver testing. Testing this hypothesis will require an initial evaluation for liver disease with liver function testing and imaging, and then histologic confirmation by liver biopsy.
Study Type	Interventional
Study Phase	Phase 1
Study Design	Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening
Condition	Liver Fibrosis Alpha-1 Antitrypsin Deficiency AAT Deficiency AATD
Intervention	Device: Abdominal ultrasound Abdominal ultrasound will be done at the screening visit and year 3 visit. The purpose of the ultrasound is to evaluate for the presence of liver fibrosis. Other Names: SonoSite Edge Ultrasound SystemProcedure: History and physical Every study participant will be asked about their medical history and will have a physical exam done at the screening, year 1, year 2, and year 3 visits. Other Names: H&P exam medical history Procedure: Intravenous catheter Every study participant will have and intravenous catheter (IV) placed at every study visit. The IV will be used for the collection of blood at the screening, year 2, year 2, and year 3 visits. It will also be used for the administration of medication at the first liver biopsy, as well as the year 3 visit if the biopsy is repeated. Other Names: IVProcedure: Blood draw At the screening, year 1, year 2, and year 3 visits, every participant will have blood collected from the IV that is placed in one of their veins. Other Names: PhlebotomyOther: Liver questionnaire At the screening and year 3 visits, every subject will complete a questionnaire which involves questions regarding liver health. Other Names: QuestionnaireProcedure: Liver Biopsy Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine (a numbing medicine) injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. Once the relaxation medication and numbing medicine have been given, a sample of liver tissue will be collected using a needle biopsy device. Other Names: BiopsyDrug: Midazolam Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea). Other Names: VersedDrug: Fentanyl Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea). Other Names: Fentora Onsolis Drug: Lidocaine Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea). Other Names: XylocaineDrug: Acetaminophen Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea). Other Names: TylenolDrug: Lorazepam Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea). Other Names: AtivanDrug: Oxycodone/Acetaminophen Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea). Other Names: Percocet Tylox Drug: Ondansetron Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea). Other Names: Zofran
Study Arm (s)	Experimental: AATD ZZ Group Participants will get a history and physical (H&P) and have an intravenous catheter (IV) placed, for blood draws, at the screening and years 1-3 visits. An IV will also be placed at the liver biopsy visit(s) for the administration of medication. An abdominal ultrasound will be done at the screening and year 3 visits along with the completion of a liver questionnaire. Finally, participants will have a liver biopsy done, with the use of lidocaine, lorazepam, or midazolam and fentanyl, after the screening visit and potentially at the year 3 study visit, depending on the results of the first liver biopsy. Participants who experience pain after the liver biopsy may receive acetaminophen or oxycodone/acetaminophen. Any subject experiencing nausea may receive ondansetron.

Recruitment Information[ + expand ][ + ]

Recruitment Status	Recruiting
Estimated Enrollment	100
Estimated Completion Date	April 2017
Estimated Primary Completion Date	April 2016
Eligibility Criteria	Inclusion Criteria: - Alpha-1 Antitrypsin deficiency confirmed to be PI*ZZ by both genotype and phenotype who have serum AAT levels less than or equal to 11 µM; - Age range from 21-70; - Willingness to consent to liver biopsy; - Ability to travel to UF as necessary by protocol; and - Platelet count greater than or equal to 75,000/mm3 and an INR less than or equal to 1.5. Exclusion Criteria: - Hemophilia, anticoagulant therapy that cannot be interrupted briefly, malignancy, or any other condition that would compromise the safety of a liver biopsy; - Any known pre-existing medical condition that might interfere with the patient's participation in and completion of the study or any condition, which in the opinion of the investigator would make the patient unsuitable for enrollment; - Active substance abuse including, but not limited to, alcohol, intravenous or, inhaled drugs; - History of adverse reactions or allergy to the local anesthetic, sedative, or pre-medication used for the percutaneous liver biopsy; - Poor venous access making the subject unable to complete the required laboratory testing schedule; and - Females who are pregnant or lactating at time of enrollment. Should a female subject become pregnant during the follow up period after the initial liver biopsy, continued participation would be allowed if the following conditions are met: the subject desires to continue; a discussion of risk and benefits of participation between the principal investigator and the subject has occurred; and no liver biopsy would be performed in the follow up period.
Gender	Both
Ages	21 Years
Accepts Healthy Volunteers	No
Contacts	Contact: Tracie L Kurtz, RN 866-229-6313 tlkurtz@ufl.edu
Location Countries	United States

Administrative Information[ + expand ][ + ]

NCT Number	NCT01810458
Other Study ID Numbers	63-2013
Has Data Monitoring Committee	No
Information Provided By	University of Florida
Study Sponsor	University of Florida
Collaborators	Not Provided
Investigators	Principal Investigator: Mark Brantly, MD University of Florida
Verification Date	October 2013

Locations[ + expand ][ + ]